Edgen Stock·Sep 13 2025, 20:11戻る
戻る
I-Mab Shifts Strategic Focus to Gastric Cancer Therapy Givastomig, Market Evaluates New Trajectory
Edgen Stock·Sep 13 2025, 20:11
[1] I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market (NASDAQ:IMAB) (https://seekingalpha.com/article/4821757-i-ma ...)[2] I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update (https://www.globenewswire.com/news-release/20 ...)[3] Bridgewater's Exit from China: A Strategic Shift and the Roadmap to Undervalued Opportunities - AInvest (https://vertexaisearch.cloud.google.com/groun ...)